Hot Features
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative col... Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.69 | -3.36257309942 | 20.52 | 21.52 | 19.27 | 501122 | 20.41958142 | CS |
| 4 | -2.36 | -10.635421361 | 22.19 | 24.16 | 19.27 | 443606 | 21.71999847 | CS |
| 12 | -3.2 | -13.89491967 | 23.03 | 29.07 | 19.27 | 378658 | 23.32850906 | CS |
| 26 | 0.56 | 2.90607161391 | 19.27 | 33.2 | 13.885 | 486939 | 24.61990067 | CS |
| 52 | -1 | -4.8007681229 | 20.83 | 33.2 | 13.885 | 425953 | 24.40018142 | CS |
| 156 | -1 | -4.8007681229 | 20.83 | 33.2 | 13.885 | 425953 | 24.40018142 | CS |
| 260 | -1 | -4.8007681229 | 20.83 | 33.2 | 13.885 | 425953 | 24.40018142 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.